Tirzepatide established what dual agonism could do. Adding GIP to GLP-1 produced 22.5% weight loss in SURMOUNT-1, a 7.6 percentage point gain over semaglutide's 14.9%. The next question was obvious. If two receptors beat one, do three beat two? Retatrutide's TRIUMPH-4 trial answered the question with 28.7% weight loss at the top dose. The third receptor was glucagon, and it added another 6.2 percentage points on top of what tirzepatide had already proven.
That is the headline story of triple agonism. The longer story is more interesting. Glucagon was the unlikely third receptor, because for decades the textbook taught that glucagon raised blood sugar and was the wrong direction for a metabolic drug. The mechanism that resolves the paradox is that GLP-1 dominates the glucose-regulation effect while glucagon contributes somewhere different: energy expenditure. The trade-off is a new safety signal. Dysesthesia, an abnormal tingling sensation, was reported by 20.9% of TRIUMPH-4 participants on the 12mg dose and is not seen in any dual-agonist trial.
This article covers what each receptor contributes, why glucagon was the surprising addition, and what the receptor progression looks like in clinical data. For the GIP-specific context that sits underneath the triple-agonism story see GLP-1 vs GIP. For the individual compound comparison that puts retatrutide alongside its competitors see the GLP-1 Comparison Chart 2026.
What dual agonism established
Tirzepatide is the only approved dual agonist in the class. Approved by the FDA in May 2022 for type 2 diabetes (Mounjaro) and November 2023 for weight loss (Zepbound), it activates the GLP-1 receptor and the GIP receptor with a single peptide. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022, PMID: 35658024, NCT04184622) reported 22.5% weight loss at the 15mg dose over 72 weeks. SURMOUNT-5 (Aronne et al., NEJM, 2025) put tirzepatide head-to-head against semaglutide and reported 20.2% versus 13.7% at 72 weeks, a direct demonstration that the dual-agonism advantage was real.
The size of that advantage was the clinical proof of concept that mattered. Until SURMOUNT-1, the field had a single receptor (GLP-1) and a ceiling around 15% weight loss. The jump to 22.5% with a second receptor was not a refinement. It was a step change. It validated the multi-receptor strategy and made the next question, what a third receptor could add, the dominant question in obesity drug development for the following five years. Retatrutide was the answer.
What glucagon brings as a third receptor
Glucagon was a counterintuitive choice. The textbook role of glucagon, secreted from pancreatic alpha cells in response to low blood sugar, is to raise blood glucose by stimulating hepatic glucose output. For a drug intended to treat type 2 diabetes alongside obesity, raising blood glucose is the wrong direction. The reason glucagon agonism made sense anyway is that the hepatic glucose effect is not the only thing the glucagon receptor does. It also stimulates lipid oxidation in the liver and raises basal energy expenditure across multiple tissues. In a compound that already contains a strong GLP-1 component, the GLP-1 effect dominates glucose regulation while the glucagon effect adds a metabolic rate signal that GLP-1 and GIP do not provide on their own.
The breakdown of what each of retatrutide's three receptors contributes:
- GLP-1 receptor — Primary appetite suppression and glucose regulationGlucose-dependent insulin release from pancreatic beta cells, suppression of glucagon from alpha cells, slowed gastric emptying, and reduced appetite signalling in the hypothalamus and brainstem. This is the foundation receptor every drug in the class activates. Without it, none of the others produce meaningful weight loss on their own.
- GIP receptor — Amplifies GLP-1 satiety, improves GI tolerabilityReceptors on pancreatic beta and alpha cells, adipose tissue, central nervous system (hypothalamus and brainstem), and bone tissue. The CNS expression appears to amplify GLP-1's satiety signalling. Adipose-tissue GIP signalling supports lipid handling. Adding GIP to GLP-1 produced a 7.6 percentage point gain in SURMOUNT-1 versus STEP 1, alongside slightly improved GI tolerability.
- Glucagon receptor — Raises energy expenditureHepatic glucagon receptors stimulate lipid oxidation and increase basal metabolic rate. This is the energy-expenditure side of the weight loss equation, where GLP-1 and GIP work on the energy-intake side. The trade-off appears in the dysesthesia signal at 20.9% in TRIUMPH-4 12mg, the only safety signal on the chart that is unique to triple agonism.
The intake-versus-expenditure framing is the cleanest way to think about why three receptors beat two. GLP-1 and GIP both act primarily on energy intake, suppressing appetite and improving postprandial metabolism. Glucagon adds a separate channel: energy expenditure. Two compounds working on the same side of the balance produce diminishing returns past a certain point. Adding a compound that works on the other side opens new headroom. That is the mechanistic argument for why the receptor-stacking pattern continues, and the TRANSCEND-T2D-1 trial (March 2026) provided the diabetes-specific data point, with retatrutide 12mg producing a 2.0% A1C reduction and 16.8% weight loss at 40 weeks in type 2 diabetes patients.
The receptor-by-receptor progression
The pattern across the class is consistent. Each receptor added produces roughly 5 to 7 percentage points of additional weight loss in head-to-head trial data. The progression looks additive rather than competitive, which suggests the mechanisms combine without significant interference.
| Compound | Receptors | Trial | Top-dose loss | Gain over previous |
|---|---|---|---|---|
| Liraglutide | GLP-1 | SCALE | 8.0% | Baseline |
| Semaglutide | GLP-1 | STEP 1 | 14.9% | +6.9 pp |
| Tirzepatide | GLP-1 + GIP | SURMOUNT-1 | 22.5% | +7.6 pp |
| Retatrutide | GLP-1 + GIP + Glucagon | TRIUMPH-4 | 28.7% | +6.2 pp |
Liraglutide and semaglutide share a single receptor mechanism but differ in dose, half-life, and exposure. The 6.9 point jump from liraglutide to semaglutide reflects what better dosing of a single receptor can achieve. The 7.6 point jump from semaglutide to tirzepatide reflects the addition of GIP. The 6.2 point jump from tirzepatide to retatrutide reflects the addition of glucagon. The pattern is the strongest evidence available that the receptor-stacking strategy produces predictable returns within the current ceiling. Whether that ceiling sits closer to 30% or extends further is what the next generation of compounds is designed to test.
The dysesthesia trade-off
The new safety signal that arrived with triple agonism is dysesthesia, an abnormal sensation typically described as tingling, prickling, or pins and needles, usually in the extremities. In TRIUMPH-4, dysesthesia was reported by 20.9% of participants on the 12mg dose, 8.8% on the 9mg dose, and 0.7% on placebo. It was not reported in retatrutide's Phase II trial (Jastreboff et al., NEJM, 2023, PMID: 37366315), which means it only became visible at the larger Phase III sample size. It is absent in tirzepatide's SURMOUNT trials and absent in semaglutide's STEP and SELECT trials, which points to glucagon receptor activation as the likely cause.
The mechanism remains uncertain. Glucagon receptors are expressed in peripheral nerves and several CNS regions, and activation could plausibly alter sensory signalling at either site. The dose-response relationship (0.7% at placebo, 8.8% at 9mg, 20.9% at 12mg) supports a dose-dependent on-target effect rather than an unrelated side effect. For most participants the sensation is mild and self-limiting. For a minority it is more disruptive, and dose adjustment to 9mg from 12mg appears to reduce the rate by more than half. This is the trade-off the field has accepted for the additional 6.2 percentage points of weight loss the third receptor produces. For the broader safety context across the class see GLP-1 Safety Profile.
Where multi-agonism is going next
Retatrutide is the most advanced triple agonist but it is not the only multi-receptor candidate in late-stage trials. The landscape now splits into three strategies. The first is pure receptor stacking, extending the GLP-1 + GIP + glucagon backbone to four receptors with candidates that add amylin or other metabolic targets in preclinical or early clinical testing. The second is selective dual combinations that skip GIP entirely, with mazdutide (Innovent) and survodutide (Boehringer/Zealand) testing whether GLP-1 + glucagon alone can match GLP-1 + GIP + glucagon at lower side-effect cost. The third is co-administration, exemplified by Novo's CagriSema (cagrilintide + semaglutide), which adds an amylin analogue to a GLP-1 agonist as two molecules rather than one.
The next two years of trial readouts will determine which of these strategies wins out. The receptor-stacking pattern of 5 to 7 percentage points per receptor cannot continue indefinitely, and somewhere in the next generation a ceiling should appear. Whether that ceiling sits at 30%, 35%, or higher is the open question. For the practitioner-grade comparison of the two compounds at the centre of the dual category right now see Semaglutide vs Tirzepatide.
Frequently Asked Questions
What is the difference between a triple agonist and a dual agonist?
A dual agonist activates two receptors. A triple agonist activates three. In the GLP-1 class, tirzepatide is the only approved dual agonist (GLP-1 + GIP). Retatrutide is the lead triple agonist in clinical development, adding the glucagon receptor as the third target. Each additional receptor activates a different metabolic pathway, and Phase III data show the additional pathways translate into additional weight loss.
What does adding glucagon to GLP-1 and GIP actually do?
Glucagon receptor activation increases energy expenditure. Where GLP-1 and GIP work mainly by reducing energy intake (suppressing appetite, slowing gastric emptying, improving insulin response), glucagon works on the other side of the equation by increasing the metabolic rate. It stimulates hepatic lipid oxidation and raises basal energy expenditure. In Phase III trials, this translated to roughly 6 percentage points of additional weight loss on top of the dual-agonism benefit.
Doesn't glucagon raise blood sugar? Why use it for weight loss?
Native glucagon does raise blood glucose by stimulating hepatic glucose output, which is why this seemed counterintuitive for years. The resolution is that retatrutide's GLP-1 component dominates the glucose-regulation effect. GLP-1 stimulates glucose-dependent insulin release and suppresses glucagon's hyperglycaemic effect at the pancreas. Net glucose control is preserved or improved. The TRANSCEND-T2D-1 trial reported a 2.0% A1C reduction at 12mg over 40 weeks in type 2 diabetes patients, alongside 16.8% weight loss.
How much extra weight loss does the third receptor produce?
TRIUMPH-4 reported 28.7% weight loss with retatrutide 12mg at 68 weeks. SURMOUNT-1 reported 22.5% with tirzepatide 15mg at 72 weeks. The gap is 6.2 percentage points. The roughly comparable jump from semaglutide (GLP-1 only, 14.9%) to tirzepatide (GLP-1 + GIP, 22.5%) was 7.6 percentage points. Each additional receptor adds roughly 5 to 7 percentage points, and the pattern holds across the class.
What is dysesthesia and why is it specific to triple agonists?
Dysesthesia is an abnormal skin sensation, most commonly described as tingling, prickling, or a pins-and-needles feeling. In TRIUMPH-4, dysesthesia was reported by 20.9% of participants on retatrutide 12mg, 8.8% on 9mg, and 0.7% on placebo. It was not reported in the Phase II trial and only appeared at scale in Phase III. The signal is absent in GLP-1-only and GLP-1 + GIP compounds, which strongly suggests glucagon receptor activation as the cause. Eli Lilly has stated that dysesthesia does not generally lead to discontinuation, though the overall TRIUMPH-4 discontinuation rate at 12mg was 18.2% versus 4% on placebo.
Is retatrutide the only triple agonist in development?
It is the most advanced and the only one in Phase III for obesity. Other triple-agonist candidates exist in earlier-stage development across multiple companies, but the field is currently dominated by dual agonists in late-stage trials. Mazdutide (Innovent) and survodutide (Boehringer/Zealand) are dual GLP-1 + glucagon agonists in Phase III, skipping GIP entirely. Whether the GLP-1 + glucagon combination produces results comparable to GLP-1 + GIP + glucagon is one of the open questions the next two years of trial readouts should answer.
Will quadruple agonists be the next step?
Possibly. Several companies have published preclinical data on compounds that add a fourth receptor (most often amylin or glucose-dependent insulinotropic peptide variants) to the GLP-1 + GIP + glucagon backbone. Whether the receptor-stacking pattern of roughly 5 to 7 percentage points per receptor continues at four receptors is unknown and there is reason to think it may not. Mechanistic ceilings exist, and side-effect burden tends to compound as more receptors are activated. The next answer is more likely from amylin co-agonists like CagriSema (cagrilintide + semaglutide) than from a single quadruple-agonist molecule.
Should patients wait for retatrutide instead of starting a dual agonist?
Generally no. Retatrutide is investigational and not expected to receive FDA approval before late 2027 or 2028, with NDA submission expected late 2026. Tirzepatide is approved, available, and produces 22.5% weight loss in trials and roughly 60 to 75% of that figure in real-world use. The 6.2 percentage point gap between dual and triple agonism is real but it is a fraction of the gap between any treatment and no treatment. For patients with active obesity or type 2 diabetes, the right answer is usually to start a currently approved compound and revisit the question if and when retatrutide reaches market.
This article is for informational and educational purposes only and does not constitute medical advice. Retatrutide is investigational and has not been approved by the FDA, EMA, MHRA, or any other regulatory agency as of May 2026. Tirzepatide is approved for weight management and type 2 diabetes; prescribing information, contraindications, and side effects should be reviewed in the official product label. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Last updated: May 2026.